The 7 analysts offering 12-month price forecasts for FibroGen Inc have a median target of 18.00, with a high estimate of 30.00 and a low estimate of 11.00. The median estimate represents a +66.51% increase from the last price of 10.81.
The current consensus among 10 polled investment analysts is to Hold stock in FibroGen Inc. This rating has held steady since September, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.12
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.